Clinical Trial Update: A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing lenvatinib to sorafenib as first-line therapy for unresectable hepatocellular carcinoma has completed; results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Eisai Limited | Conditions: Hepatocellular Carcinoma (HCC) | Phase 3 | Status: COMPLETED | Results posted: 2018-09-25